Calcium AEP: Membrane Integrity Factor Aids Treatment of Multiple Sclerosis, Asthma and Osteoporosis
Ward Dean, MD and Jim English
In 1941, a unique form of calcium, Calcium 2-amino ethyl phosphoric acid (Ca-AEP or Ca-2AEP) was discovered by the eminent biochemist Erwin Chargaff. Chargaff found that Ca-AEP was a vital component in the structure of cell membranes. The significance of Chargaff’s work was largely ignored for the next two decades, but studies over the last 30 years have shown that Ca-AEP plays a vital role in maintaining cell membrane integrity and improving cellular functions. It has also been shown to be effective in supporting a host of conditions, including multiple sclerosis, diabetes, asthma and immune disorders.
A New Vitamin?
Ca-AEP is one of a number of colamine phosphates—vitamin-like metabolites and cell membrane integrity factors, that are required for cellular membrane functions. Among these functions, Ca-AEP is known to acts as:
1) Cell Sealer and Protector
Cells allow entry of vital nutrients through pores spread across the cellular membrane. Two types of pores predominate: free lipid pores and peptide-lined transport pores. Lipidic pores can permit the unwanted penetration into cells by harmful agents. Ca-AEP decreases water solubility and seals the lipid cellular membrane pores, decreasing the permeability of the outer cell membrane by foreign substances. This action protects cells from invasion by toxins, bacteria, viruses, antibodies and other harmful agents.
2) Electrolyte and Nutrient Carrier
Ca-AEP facilitates the cellular exchange of inorganic electrolytes in cells and aids the absorption of nutrient substances such as fatty acids, amino acids, carbohydrates, vitamins, hormones and steroids through the ‘active transport pores’ of cell membranes.
3) Maintains Cell Electrical Charge
Ca-AEP maintains and repairs cellular neurotransmission, vital for the electrobiological connection of cells. Ca-AEP helps the cells to retain the electrical charges of calcium, potassium and magnesium ions residing on the membrane surface where they serve to increase the conductivity of nerve tissue. It does this by causing calcium and other minerals to bind to cellular membranes where they serve as electrical condensers, essential for cellular regulation.
This condenser function of the cell membrane plays an active role in disease prevention. If there is an insufficient amount of colamine phosphate salts, the cell’s electrical charge and condenser function will be abnormal. A significant loss of the electrical charge of the cell membrane may be catastrophic—especially for the circulatory system, immune system and neuromuscular system.
Diseases Involving Disturbance of Cell Membranes
Some illnesses are initiated when the body is unable to synthesize and incorporate into cell membranes adequate amounts of colamine phosphates such as Ca-AEP. Conversely, restoring levels of Ca-AEP to proper levels has been shown to improve membrane integrity and produce actions that are both therapeutic and preventive in nature. Among the diseases initiated or influenced by disturbances in cellular membranes are:
- Multiple Sclerosis and sclerotic disorders, including Amyotrophic lateral sclerosis and progressive systemic sclerosis
- Inflammatory disorders, including rheumatoid arthritis
- Diabetes, both Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent Diabetes Mellitus (NIDDM)
- Diabetic complications, including diabetic nephropathy and retinopathy
- Lung diseases, including asthma, emphysema and other conditions characterized by poor gaseous exchange in the alveoli
- Immune disorders such as sarcoidosis
The first trial applications of Ca-AEP were for the treatment of multiple sclerosis (MS). In 1967 the German Health Authority approved the use of Ca-AEP for MS. MS, an inflammatory demyelinating condition, is one of the most common diseases of the central nervous system (brain and spinal cord). Myelin, the fatty material that surrounds nerves, acts as an insulator, much like the covering of an electric wire.
It is the speed and efficiency with which electrical impulses are conducted that permits smooth, rapid and coordinated movements to be performed with little conscious effort. In MS, the loss of the myelin sheath (demyelination) leads to a disruption in the ability of the nerves to conduct electrical impulses. It is believed that the loss of the ability of nerves to transmit impulses rapidly to and from the brain is what produces the various symptoms of MS.
The sites where myelin is lost (plaques or lesions) appear as hardened scars. In multiple sclerosis these scars appear at different times and in different areas of the brain and spinal cord — thus, the term Multiple Sclerosis literally means “many scars.”
An analysis of more than 2,000 patients who were treated with colamine salts in Germany over the course of 24 years revealed greater efficacy from Ca-AEP treatments than other known treatments. In 1986, Dr. George Morrissette conducted a retrospective poll of patients in the USA who originally had begun Ca-AEP treatment in Germany for MS. 82% of the almost 300 patients that entered the study showed a positive benefit from Ca-AEP therapy. And when treatment began in the early stages of MS, positive results rose to 92%.
According to the work of Dr. Hans Nieper, MS should not be viewed as just a neurological disorder. MS is a generalized disease of the cellular membrane system that affects the nerves, bones, kidneys, lungs, red blood cells, blood vessels and many other organs and sites.
Long-term observation of Ca-AEP’s effects on more than 2,000 MS patients revealed a host of additional benefits. MS patients receiving Ca-AEP showed less signs of aging in their outward appearance, increased tissue elasticity and skeletal firmness and a marked absence of osteoporosis. Second to the destruction of the myelin sheath of the nerve fibers, MS patients are especially at risk of kidney infection due to insufficient membrane polarization at the cellular level.
While formerly one-third of all MS patients died due to lost nerve functions, one-third from increased tendency to bone fractures, and the last one-third from kidney failure, only two patients out of 2,200 treated with Ca-AEP suffered from these problems. Unusual bone fractures and problems with kidney functions were not observed at all.
The supplementation of Ca-AEP repairs cell membrane function and maintains it at optimal levels. It raises the depressed energy in the membrane system of the nerves’ myelin sheath of MS patients by several-fold, restoring proper synaptic function in the affected organs.
MS patients receiving Ca-AEP treatments have experienced facial and upper extremity mobility, body heat generation, greater relief from exhaustion and decreased spasticity.
Osteoporosis and Bone Fractures
Every year over 1.3 million elderly Americans suffer from spontaneous bone fractures due to osteoporosis and decalcification of the bones. Both men and women experience a loss in bone density in middle age, but postmenopausal women are particularly vulnerable due to declines in estrogen production.
Osteoporosis is not a true biochemical disease, but is being considered by some to be an electromagnetic illness. The accumulation of crystallized bone salts requires the steady pulsation of electric or electromagnetic potential at the surface of the cell membrane of bone tissues. These pulses create a “piezoelectric” pressure which, when applied to the salt crystals, builds up apatite (calcium phosphate minerals) which in turn hardens and strengthens the bone. Ca-AEP is indispensible in supporting the function of the cell membranes that form bone.
After 30 years of Ca-AEP and Calcium Orotate therapies with over 3,500 patients with multiple sclerosis, the risk of bone fractures was drastically reduced. Furthermore, surgeons in six surgical centers located in USA and Europe reported finding extremely solid bone when implanting new joints in patients who were taking Ca-AEP combined with calcium and magnesium orotate for at least four years prior to their surgeries.
Ca-AEP, in conjunction with calcium orotate supplements, has decreased bone decalcification and increased bone density and strength. This most likely is a result of Ca-AEP’s ability to improve the condenser function of the cell membranes of bone tissues.
Ca-AEP protects the lungs against disease and repairs lung damage by improving the gaseous exchange mechanism (uptake of oxygen and elimination of carbon dioxide) of the alveoli. Colamine phosphate salts have eliminated the tendency toward asthma, the development of emphysema and elevated pulmonary pressure.
Ca-AEP’s actions in normalizing gas exchange in the lungs may be the mechanism by which it benefits patients with asthma and degenerative lung diseases. Researchers pointed out that after a few weeks of therapy with Ca-AEP, asthmatic reactions have subsided and almost disappeared. In addition, the bone-thinning effects of these diseases is prevented by Ca-AEP. These disorders of gas metabolism cause increased carbon dioxide stress in the blood, resulting in the mobilization of calcium from the bones which causes them to decalcify.
Ca-AEP has produced good results in treating Insulin-dependent Diabetes Mellitus (IDDM), Non-insulin Dependent Diabetes Mellitus (NIDDM) and the complications of diabetes. The treatment of IDDM with Ca-AEP has resulted in lowered insulin requirements and in reduced sugar excretion. Ca-AEP’s theraputic effect on diabetics is partly due to its inhibiting pancreatic autoimmune disorders.
Ca-AEP has improved the regulation of blood glucose in NIDDM. NIDDM is not a problem of reduced insulin production, but rather insulin resistance and an inability to transport glucose into cells. In such cases, eating excess carbohydrates causes an abnormal rise in blood sugar. If, on the other hand, the individual does not eat, hypoglycemia may result. When NIDDM patients are treated with Ca-AEP, this abnormality practically disappears, because glucose transport into cells is restored.
In diabetes the problem is not just the increase in blood sugar, but the consequences of exposure to both elevated blood sugar and elevated insulin over the course of a lifetime. Elevated glucose levels produce toxic metabolites that are deposited in and damage numerous structures of the body ranging from the red blood hemoglobin to the cell membranes of blood vessels. This effect leads to degenerative problems in 20-30 years.
Ca-AEP is beneficial in preventing and treating the complications of diabetes. It seals the cell membrane that prevents toxic glucose metabolites from entering and damaging the cells.
In the United States, diabetes is the second most frequent cause of blindness. Diabetic retinopathy is caused by damage to the small vessels in the retina as a consequence of sugar deposits in the cell membranes. Diabetic retinopathy has been prevented and reversed by treatment with Ca-AEP.
In European clinics, Ca-AEP is used in the treatment of gastritis, duodenitis colitis, ulcer pain and other disturbances of the GI tract. Ca-AEP therapies have also produced good results in relieving tissue inflammation due to gastritis and GI tract autoimmune disorders.
Ca-AEP has produced exceptional therapeutic effects in patients with chronic kidney diseases. The disorders include nephritis, nephrosis, nephrosclerosis, cystic kidney and diabetic nephropathy (chronic vessel and membrane damage in the kidney due to diabetes).
The kidneys are severely endangered by diabetes on a long-term basis. The glomeruli, a small cluster of capillaries in the kidney, are slowly destroyed by the burden of glucose. It is a diabetic’s fate to frequently suffer kidney failure. Ca-AEP not only protects the kidneys against damage from diabetes and hypertension, but also ameliorates the initial forms of diabetic kidney damage.
In addition, the increase in blood pressure caused by diabetic nephropathy and abnormal elimination of protein are often reduced, sometimes to completely normal values by Ca-AEP therapy.
Rheumatoid Arthritis and Anti-inflammation
Rheumatoid arthritic patients who were treated with Ca-AEP have initially shown improved calcification of their joints and reduced inflammation. Consequentially, Dr. Hans Nieper has recommended Ca-AEP for the prophylaxis of rheumatic deformities of the joints. The anti-inflammatory effects of Ca-AEP are a result of complex calcium being introduced into the cell membrane, aiding its ability to prevent pro-inflammatory materials from entering cells.
For many inflammatory tissue disorders, treatment with Ca-AEP has produced results that were judged as effective as, and in some cases more effective, than corticosteroid therapy. These disorders included encephalitis, gastritis, nephritis, nephrosis, arteritis, and spondylitis.
One should consider the fact that treatment with Ca-AEP is non-toxic. On the other hand, corticosteroid therapy may result in many harmful side effects that become more prevalent over the course of treatment.
The role of Ca-AEP has been studied for more than 30 years. This vitamin-like factor, like carnitine and coenzyme Q10, appears to be very important for optimum health. The illnesses discussed above, may be initiated by inadequate amounts of colamine phosphates and respond favorably to Ca-AEP supplement therapy. Furthermore, I believe that substances which have such a wide range of clinical benefits in such a diverse number of pathological conditions may have profound anti-aging/life-extending effects. This is particularly likely in the case of Ca-AEP which specifically effects the integrity and functional capacity of cellular membranes and their receptors.
1. Nieper HA. Mineral transporters. New Dynamics of Preventive Medicine; 1974: 43-54.
2. Nieper HA. A clinical study of the calcium transport substance Ca l-d1-aspartate and Ca 2-aminoethyl phosphate as potent agents against autoimmunity and other anticytological aggressions. Agressologie. 1967, 8:1-12.
3. Nieper HA. A comparative study of the clinical effect of Ca-1-d1-aspartate (Calciretard), of Ca-2-aminoethanol phosphate (Ca-EAP) and of the cortisones. Agressologie. 1968, 9: 471-474.
4. Nieper, HA. Suppression of cancer development by calcium colamine phosphate and by calcium-l-d1-aspartate. The Townsend Letter for Doctors and Patients. December 1995.
5. Nieper HA. Impairment of digestive potential in MS and osteoporosis patients. Townsend Letter for Doctors and Patients. February/March 1991.
6. Ferrari V and Harkness RD: Increase of 2-amino-ethyl-phosphate in regenerating liver tissue, J Phsiol, 113: 27, 1951.
7. Segal W: Biosynthesis of 2-aminoethaneohosphoradimic acid: A phosphoramidic acid re-arrangement, Nature, 5017: 1284 1965.
8. Narrod SA and Jakoby WB: Metabolism of ethanolamine J biol chem 239: 2189, 1964.